Treatment with a Chimeric CD4 Monoclonal Antibody is Associated with a Relative Loss of CD4+/CD45RA+Cells in Patients with Rheumatoid Arthritis
- 28 February 1997
- journal article
- research article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 10 (1) , 87-97
- https://doi.org/10.1006/jaut.1996.0113
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Treatment of Rheumatoid Arthritis with a Chimeric CD4 Monoclonal Antibody (cM‐T412): Immunopharmacological Aspects and Mechanisms of ActionScandinavian Journal of Immunology, 1994
- Chimeric cd4 monoclonal antibody cm‐t412 as a therapeutic approach to rheumatoid arthritisArthritis & Rheumatism, 1993
- Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritisArthritis & Rheumatism, 1993
- Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibodyInternational Immunology, 1993
- From Antilymphocyte Serum to Therapeutic Monoclonal Antibodies: First Experiences with a Chimeric CD4 Antibody in the Treatment of Autoimmune DiseaseImmunological Reviews, 1992
- Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal AntibodiesImmunological Reviews, 1992
- The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritisArthritis & Rheumatism, 1992
- Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibodyArthritis & Rheumatism, 1991
- In vivo immunomodulation by monoclonal anti-L3T4Cellular Immunology, 1987
- Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.The Journal of Experimental Medicine, 1985